MX2011012358A - Uso de inhibidores de la actividad de zdhhc2 para la modulacion de la adipogenesis. - Google Patents

Uso de inhibidores de la actividad de zdhhc2 para la modulacion de la adipogenesis.

Info

Publication number
MX2011012358A
MX2011012358A MX2011012358A MX2011012358A MX2011012358A MX 2011012358 A MX2011012358 A MX 2011012358A MX 2011012358 A MX2011012358 A MX 2011012358A MX 2011012358 A MX2011012358 A MX 2011012358A MX 2011012358 A MX2011012358 A MX 2011012358A
Authority
MX
Mexico
Prior art keywords
adipogenesis
zdhhc2
activity
modulation
inhibitors
Prior art date
Application number
MX2011012358A
Other languages
English (en)
Inventor
Diana Hall
Maria Jimenez
Carine Poussin
Bernard Thorens
Original Assignee
Sanofi Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanofi Sa filed Critical Sanofi Sa
Publication of MX2011012358A publication Critical patent/MX2011012358A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1137—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/7105—Natural ribonucleic acids, i.e. containing only riboses attached to adenine, guanine, cytosine or uracil and having 3'-5' phosphodiester links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/713—Double-stranded nucleic acids or oligonucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/48—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving transferase
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/14—Type of nucleic acid interfering N.A.
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/90—Enzymes; Proenzymes
    • G01N2333/91—Transferases (2.)
    • G01N2333/91045—Acyltransferases (2.3)
    • G01N2333/91051—Acyltransferases other than aminoacyltransferases (general) (2.3.1)

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Diabetes (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biophysics (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Plant Pathology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Virology (AREA)
  • Analytical Chemistry (AREA)
  • Immunology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)

Abstract

La presente invención se refiere a Zdhhc2, un nuevo objetivo implicado en la modulación de la adipogénesis. Usando un método con ARNsi, los inventores han demostrado que la disminución de la actividad de Zdhhc2 en tejido adiposo induce una disminución de la adipogénesis. Así, la presente invención se refiere a moduladores de la actividad de Zdhhc2 así como a ensayos de tamizado para la identificación de moduladores de la actividad de este objetivo, y a su uso, especialmente en composición farmacéutica, para modular la adipogénesis y tratar así la obesidad y trastornos relacionados.
MX2011012358A 2009-05-20 2010-05-19 Uso de inhibidores de la actividad de zdhhc2 para la modulacion de la adipogenesis. MX2011012358A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP09305467A EP2253705A1 (en) 2009-05-20 2009-05-20 Use of inhibitors of Zdhhc2 activity for modulation of adipogenesis
PCT/IB2010/052225 WO2010134032A1 (en) 2009-05-20 2010-05-19 Use of inhibitors of zdhhc2 activity for modulation of adipogenesis

Publications (1)

Publication Number Publication Date
MX2011012358A true MX2011012358A (es) 2011-12-08

Family

ID=41137727

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2011012358A MX2011012358A (es) 2009-05-20 2010-05-19 Uso de inhibidores de la actividad de zdhhc2 para la modulacion de la adipogenesis.

Country Status (9)

Country Link
US (2) US8841270B2 (es)
EP (2) EP2253705A1 (es)
CN (1) CN102459594B (es)
AR (1) AR076881A1 (es)
AU (1) AU2010250807A1 (es)
CA (1) CA2762813A1 (es)
MX (1) MX2011012358A (es)
NZ (1) NZ596525A (es)
WO (1) WO2010134032A1 (es)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2021062124A2 (en) * 2019-09-25 2021-04-01 Brown University Methods and compositions for treating, preventing or reversing obesity and obesity-related disorders by opsin 3 regulation of hypothalamic melanocortin receptors

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2685346B1 (fr) 1991-12-18 1994-02-11 Cis Bio International Procede de preparation d'arn double-brin, et ses applications.
US6384087B1 (en) * 2000-09-01 2002-05-07 University Of Tennesseee Research Corporation, Inc. Materials and methods for the treatment or prevention of obesity
AU2002212246A1 (en) * 2000-09-19 2002-04-02 Bayer Aktiengesellschaft Regulation of human serine palmitoyltransferase-like enzyme
US8404655B2 (en) * 2007-05-18 2013-03-26 University Of Florida Research Foundation, Inc. Inhibition of palmitoyl acyl transferase expression and/or activity for the regulation of antiproliferative factor activity

Also Published As

Publication number Publication date
WO2010134032A1 (en) 2010-11-25
EP2432879A1 (en) 2012-03-28
US20120165391A1 (en) 2012-06-28
AR076881A1 (es) 2011-07-13
US20150057334A1 (en) 2015-02-26
EP2253705A1 (en) 2010-11-24
NZ596525A (en) 2013-12-20
US8841270B2 (en) 2014-09-23
CA2762813A1 (en) 2010-11-25
AU2010250807A1 (en) 2011-12-08
CN102459594A (zh) 2012-05-16
CN102459594B (zh) 2014-10-15

Similar Documents

Publication Publication Date Title
MX2015005536A (es) Tratamiento de canceres utilizando moduladores de las isoformas de pi3 cinasa.
WO2011139489A3 (en) Compounds that modulate intracellular calcium
UA108912C2 (uk) БІЛОК, ЯКИЙ ЗВ'ЯЗУЄ TNF-α
MX337711B (es) Compuestos que modulan el calcio intracelular.
WO2012170931A3 (en) Compounds that modulate intracellular calcium
MX2020011749A (es) Composiciones y metodos para modular la expresion de pkk.
MY157445A (en) Compounds that modulate intracellular calcium.
CO6551721A2 (es) Moduladores de cinasa novedosos
MY163004A (en) Modulation of signal transducer and activator of transcription 3 (stat3) expression
MY165620A (en) Cyclopropylamines as lsd1 inhibitors
BR112013027774A2 (pt) novos compostos como moduladores de proteína quinases
MX2010002712A (es) Compuestos que modulan calcio intracelular.
WO2012040499A3 (en) Metabolic inhibitors
MX2009012623A (es) Moduladores de cinasa heterociclicos.
WO2012037155A3 (en) Tyrosine kinase inhibitors
MX2012004078A (es) Compuestos y composiciones como moduladores de la actividad de gpr119.
WO2010034011A3 (en) Phenylthiophenyldihydrobenzothiazepine inhibitors of store operated calcium release
WO2011139765A3 (en) Compounds that modulate intracellular calcium
WO2011034962A3 (en) Compounds that modulate intracellular calcium
EP2563794A4 (en) INHIBITORS OF TYROSINE KINASE PROTEIN ACTIVITY AND THEIR APPLICATIONS TO THE TREATMENT OF OPHTHALMIC DISORDERS
WO2012170951A3 (en) Compounds that modulate intracellular calcium
WO2011097522A3 (en) Combination methods for treatment of disease
WO2011109551A3 (en) Compounds that modulate intracellular calcium
WO2014047519A3 (en) Inhibitors of beta-hydrolase for treatment of cancer
MX2011012358A (es) Uso de inhibidores de la actividad de zdhhc2 para la modulacion de la adipogenesis.

Legal Events

Date Code Title Description
FA Abandonment or withdrawal